Loading…
Based on limited metadata without access to the full warning letter text, Carahealth received an FDA warning in March 2020 regarding drug products. The specific violations cannot be detailed as the subject line is unavailable; however, the warning indicates regulatory concerns serious enough to warrant formal FDA enforcement action. The warning was issued under FDA drug product authority, though the specific issuing office is not identified in the available metadata. To understand the precise nature and scope of violations cited, the complete warning letter would need to be reviewed.